Because of the delays in one patient's healthcare, her cancer had spread to bone and lung. She had wasted 18 months on the waitlist. I have hundreds of stories like this.
Eli Lilly and Co. is seeking U.S. Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after the recently approved Leqembi from Japanese drugmaker Eisai.
Who would object to a more efficient healthcare system, where money is spent on doctors and nurses, as opposed to the bureaucrats who contribute to patient suffering?
When it comes to fixing Canada’s ailing healthcare systems, governments have often failed to set that baseline—so it’s difficult to know how well the treatment has worked.
